Prevention, Diagnosis & Treatment
Bayer’s brands treat and prevent conditions to improve quality of life.
September 20, 2019
Bayer data at ESMO 2019 highlights innovation in cancer research
Bayer will present new data from the company's expanding oncology business at the European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 to October 1 in Barcelona,...
August 08, 2019
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on...
July 30, 2019
FDA approves Bayer's Nubeqa® (darolutamide), a new treatment for men with non-metastatic castration-resistant prostate cancer
The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant...
Last Updated: September 19, 2018